Migraine and Headache

Latest News

FDA Clears Hand-Held Vagus Nerve Stimulator for Migraine Prevention

The FDA has approved an expanded indication for the gammaCore device to include prevention of migraine.

Significant Reduction in Monthly Migraine Days Observed With Rimegepant in Prevention Trial

Biohaven announced positive topline results from a pivotal phase 2/3 study evaluating rimegepant for the preventive treatment of episodic and chronic migraine in adults.

Increasing Headache Day Frequency and Intensity Increases Risk of Additional Health Concerns

The presence of migraine and increasing headache pain intensity are associated with higher rates of anxiety, depression, inflammation, and sleep conditions, among other disorders.

Rimegepant Orally Disintegrating Tablet Now Available for Acute Treatment of Migraine

Biohaven announced that rimegepant is now available for the acute treatment of migraine with or without aura in adults.

People With Migraine Often Present With Metacognitive Dysfunctions

Compared with people without migraine, people with migraine and migraine with medication overuse headache often have deficits in metacognition.

Intranasal Ketamine Reduces Pain in Children Hospitalized for Migraine

A single-center study showed that intranasal ketamine effectively reduced pain in children with migraine from hospital admission to discharge.

Differences in Adverse Events in Phase 2 and Phase 3 Studies: The Case of Lasmiditan

Phase 2 clinical trials investigating lasmiditan reported higher incidence and severity of TEAEs, compared with the phase 3 studies.

Galcanezumab Is Relatively Safe for Up to 1 Year in Patients With Episodic and Chronic Migraine

Treatment with humanized monoclonal antibody galcanezumab for up to 1 year was safe and tolerable for episodic and chronic migraine prophylaxis.

Migraine Treatment Delivered by Microneedle Patch Under FDA Review

The FDA has accepted for review the New Drug Application (NDA) for Qtrypta™ (M207) (zolmitriptan intracutaneous microneedle system; Zosano Pharma) for the acute treatment of migraine.

Changes in Plasma Glucose Levels During Migraine Attacks

Plasma glucose levels are increased in patients with migraine with and without aura during spontaneous migraine attack compared with the interictal state.